Application of spironolactone in preparation of drug for treating human herpesvirus infection

A technology of herpes virus infection and herpes virus, which is applied in the application field of spironolactone in the preparation of drugs for the treatment of human herpes virus infection, can solve the problems of large side effects and inability to completely cure the disease, and achieve high therapeutic index and good resistance to herpes virus infection active effect

Inactive Publication Date: 2019-06-25
武汉威立得生物医药有限公司
View PDF1 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, it is a pity that these drugs have great side effects and cannot completely cure related diseases
Moreover, the long-term use of these drugs has resulted in many drug-resistant mutants of the virus

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of spironolactone in preparation of drug for treating human herpesvirus infection
  • Application of spironolactone in preparation of drug for treating human herpesvirus infection
  • Application of spironolactone in preparation of drug for treating human herpesvirus infection

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0024] Embodiment 1: spironolactone suppresses the active detection of KSHV virus activation, infectious virion production and viral DNA replication

[0025] 1 Experimental materials

[0026] 1.1 Cells and viruses

[0027] iSLK.219 cells were donated by Professor Dr.Don Ganem, and the cells contain the recombinant virus rKSHV.219 and the RTA expression system regulated by Doxycycline. In this cell, the RTA expression sequence was constructed into the pRetro-X Tet-ON inducible expression system (Clontech, Mountainview, CA), the expression of which was regulated by doxycycline, and in the presence of doxycycline , RTA expression can occur. Vero cells were preserved in our laboratory and purchased from the American Type Culture Collection (ATCC).

[0028] 1.2 Reagents

[0029] DMEM medium and FBS were purchased from Gibco. CellTiter Glo activity detection kit was purchased from Promega Company. Spironolactone was purchased from Biochempartner. SYBR mixture (iTaq TM Unive...

Embodiment 2

[0057] Detection of anti-HSV-1 and HSV-2 activity of spironolactone

[0058] 1. Experimental materials

[0059] 1.1 Cells and viruses

[0060] Vero cells were preserved in our laboratory and purchased from the American Type Culture Collection (ATCC). HSV-1 is an F strain, which is preserved by the Wuhan Institute of Virology, Chinese Academy of Sciences. HSV-2 is a G strain, which is preserved by the Wuhan Institute of Virology, Chinese Academy of Sciences.

[0061] 1.2 Reagents

[0062] DMEM medium and FBS were purchased from Gibco; CellTiter Glo activity detection kit was purchased from Promega.

[0063] 1.3 Experimental Instruments

[0064] The multi-label microplate reader and the high-content cell analyzer were purchased from PerkinElmer; the cell incubator was a product of Thermo. 2. Experimental methods and results

[0065] 2.1 Detection of cytotoxicity of spironolactone on Vero cells.

[0066] (1) Divide Vero cells into 8×10 3 Each well was seeded in a 96-well...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses application of spironolactone in preparation of a drug for treating human herpesvirus infection. We evaluate the effect of resisting Kaposi's sarcoma-associated herpes virus KSHV and herpes simplex viruses HSV-1 and HSV-2 of the spironolactone by measuring the level of infectious virion production, the level of DNA replication during lysis, or the degree of cytopathic effect caused by the virus. The spironolactone has significant antiviral activity and a dose-dependent effect, can inhibit the activation of replication during KSHV lysis with a half inhibitory concentration (IC50) of 1.145 microM to KSHV infectious virions. At non-toxic concentration, the spironolactone is effective in reducing cytopathic effect caused by HSV-1 and HSV-2. The spironolactone is a complete inhibitor of mineralocorticoids (such as aldosterone). The spironolactone is clinically used for inhibiting sodium reabsorption, potassium excretion, diuresis and the like of organisms and has thesmall toxic and side effects on the human body. The compound can inhibit replication of herpes virus in the lysis phase, and has a wide prospect of being developed into the drug for treating human herpes virus infection.

Description

technical field [0001] The invention belongs to the field of biomedicine, and in particular relates to the application of spironolactone in the preparation of medicines for treating human herpes virus infection. Background technique [0002] Herpesviridae is a family of viruses with envelope and double-stranded DNA genome. Members of this virus family can widely infect animals and humans and induce corresponding diseases. There are currently eight herpes viruses that can infect humans, mainly including: Herpes simplex virus-1 (HSV-1), Herpes simplex virus-2 (HSV-2), Cytomegalovirus (CMV), Epstein-Barr virus (EBV), Varicella zoster virus (VZV), Human Herpesvirus 6 (HHV-6), Human Herpesvirus 7 (HHV-7) and Kaposi's sarcoma-associated herpesvirus (Kaposi'ssarcoma-associated herpesvirus, KSHV). According to the genome sequence, structure and physical and chemical properties, it can be divided into three subfamilies: α-herpesvirinae, β-herpesvirinae and γ-herpesvirinae. The li...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/585A61K45/06A61P31/22
Inventor 陈绪林张海伟陈军刚
Owner 武汉威立得生物医药有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap